Experigen

Experigen is a Cambridge-based biotechnology company dedicated to developing novel small molecule therapeutics for cognitive and neurological disorders. The company's core technology centers on the epigenetic modulation of memory-related genes, specifically through the inhibition of Histone Deacetylase 2 (HDAC2). Founded by prominent scientists from MIT and the Broad Institute, Experigen aims to restore synaptic plasticity and cognitive function in patients suffering from Alzheimer's disease and other forms of dementia. Their research leverages deep expertise in neurobiology and chemical biology to create highly selective inhibitors that overcome the limitations of non-selective HDAC inhibitors. The company's lead programs target high-need areas including Alzheimer's disease and post-traumatic stress disorder.